Pathoshield

Studying antiviral effectiveness

On behalf of Pathoshield Ltd, MTIF, through Dr Elena Hunter, Research Fellow, undertook the study and evaluation of the effectiveness of a surface in reducing the infectivity of human coronavirus 229E (HCoV-229E). The antiviral effectiveness was analysed by tissue culture infectious dose 50% test using MRC-5 human lung fibroblast cells.

The results of the study enabled Pathoshield Ltd to demonstrate proof of concept of their innovative surface treatment and to go on to secure further investment for development.

Valuable proof

Olivia Brown of Pathoshield, commented on the work of MTIF to help them achieve a positive outcome for their development:

“The services provided by MTIF enabled us to obtain valuable proof of concept data and unlock further funding for development, we would definitely work with MTIF on further projects.”